Show simple item record

dc.contributor.authorRondy, Marc
dc.contributor.authorGherasim, Alin
dc.contributor.authorCasado, Itziar
dc.contributor.authorLaunay, Odile
dc.contributor.authorRizzo, Caterina
dc.contributor.authorPitigoi, Daniela
dc.contributor.authorMickiene, Aukse
dc.contributor.authorMarbus, Sierk D
dc.contributor.authorMachado, Ausenda
dc.contributor.authorSyrjänen, Ritva K
dc.contributor.authorPem-Novose, Iva
dc.contributor.authorHorváth, Judith Krisztina
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorCastilla, Jesús
dc.contributor.authorVanhems, Philippe
dc.contributor.authorAlfonsi, Valeria
dc.contributor.authorIvanciuc, Alina E
dc.contributor.authorKuliese, Monika
dc.contributor.authorvan Gageldonk-Lafeber, Rianne
dc.contributor.authorGomez, Veronica
dc.contributor.authorIkonen, Niina
dc.contributor.authorLovric, Zvjezdana
dc.contributor.authorFerenczi, Annamária
dc.contributor.authorMoren, Alain
dc.date.accessioned2018-03-14T12:42:07Z
dc.date.available2018-03-14T12:42:07Z
dc.date.issued2017
dc.identifier.citationLow 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. 2017, 22 (41) Euro Surveill.en
dc.identifier.issn1560-7917
dc.identifier.pmid29043961
dc.identifier.doi10.2807/1560-7917.ES.2017.22.41.17-00645
dc.identifier.urihttp://hdl.handle.net/10029/621621
dc.description.abstractIn a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.
dc.language.isoenen
dc.rightsArchived with thanks to Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinen
dc.titleLow 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season.en
dc.typeArticleen
dc.identifier.journalEuro Surveill 2017; 22(41):17000645en
refterms.dateFOA2018-12-18T14:10:18Z
html.description.abstractIn a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.


Files in this item

Thumbnail
Name:
eurosurv-22-41-2.pdf
Size:
125.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record